DesHDAP2 Shows Significant Synergy with Conventional Antibiotics, Despite Its Relatively Low Potency

Area of Science:

• Microbiology
• Biochemistry
• Pharmacology

Background:

• Antibiotic resistance is a growing global health threat.
• Antimicrobial peptides (AMPs) are a potential alternative or adjunct to conventional antibiotics.
• Histone-derived peptides are a class of AMPs with potential therapeutic applications.

Purpose of the Study:

• To investigate the antibacterial synergy of a novel histone-derived antimicrobial peptide, DesHDAP2.
• To evaluate the efficacy of DesHDAP2 in combination with conventional antibiotics.
• To assess the cytotoxicity of DesHDAP2 in combination therapy.

Main Methods:

• Synthesis and characterization of the histone-derived peptide DesHDAP2.
• Determination of the minimum inhibitory concentration (MIC) of DesHDAP2 against various bacterial strains.
• Assessment of synergistic activity using checkerboard assays with kanamycin, tetracycline, levofloxacin, and polymyxin B.
• Evaluation of cytotoxicity against eukaryotic cell lines.

Main Results:

• DesHDAP2 exhibited low intrinsic antimicrobial activity, especially against Gram-negative bacteria.
• DesHDAP2 demonstrated significant synergistic antibacterial effects when combined with kanamycin, tetracycline, levofloxacin, and polymyxin B.
• The combinations of DesHDAP2 and antibiotics showed no significant cytotoxicity towards eukaryotic cells.

Conclusions:

• DesHDAP2 shows promise as a component of combination therapy to combat antibiotic resistance.
• AMPs with limited individual activity can be effective in therapeutic cocktails.
• Combination therapy using DesHDAP2 offers a potentially safe and effective strategy against bacterial infections.